Provided by Tiger Trade Technology Pte. Ltd.

Fate Therapeutics

2.32
+0.02000.87%
Post-market: 2.340.0161+0.69%19:30 EDT
Volume:658.02K
Turnover:1.52M
Market Cap:278.40M
PE:-2.20
High:2.36
Open:2.34
Low:2.27
Close:2.30
52wk High:3.23
52wk Low:0.9500
Shares:120.00M
Float Shares:104.94M
Volume Ratio:0.42
T/O Rate:0.63%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0528
EPS(LYR):-1.1500
ROE:-60.75%
ROA:-26.22%
PB:1.81
PE(LYR):-2.02

Loading ...

Analysts Conflicted on These Healthcare Names: Fate Therapeutics (FATE) and Mediwound (MDWD)

TIPRANKS
·
Aug 14

Fate Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 13

Fate Therapeutics Q2 EPS $(0.25) Beats $(0.27) Estimate, Sales $2.082M Beat $1.366M Estimate

Benzinga Earnings
·
Aug 13

Fate Therapeutics - Expects Operating Runway into 2028

THOMSON REUTERS
·
Aug 13

Fate Therapeutics Q2 Operating Expenses USD 33.216 Million

THOMSON REUTERS
·
Aug 13

Fate Therapeutics Inc Expected to Post a Loss of 27 Cents a Share - Earnings Preview

Reuters
·
Aug 11

Don't Ignore The Insider Selling In Fate Therapeutics

Simply Wall St.
·
Aug 07

Fate Therapeutics Inc Expected to Post a Loss of 27 Cents a Share - Earnings Preview

Reuters
·
Aug 07

Fate Therapeutics Grants New-Hire Inducement Equity Awards, Including 37,300 Options at $2.45

Reuters
·
Aug 04

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Aug 04

Sector Update: Healthcare

MT Newswires Live
·
Jul 10

Update: Fate Therapeutics Shares Rise After FDA Clears Investigational New Drug Application for FT839

MT Newswires Live
·
Jul 10

Fate Therapeutics: FT839 Advancement and Autoimmune Potential Underpin Buy Rating, 12-Month $7 Price Target Reaffirmed

TIPRANKS
·
Jul 09

Fate Therapeutics Wins FDA IND Clearance for Dual-target CAR-T Candidate FT839

Reuters
·
Jul 09

Fate Therapeutics - Enrollment in Phase 1/2 Study of FT839 Expected to Begin in H2 2026

THOMSON REUTERS
·
Jul 09

Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate

THOMSON REUTERS
·
Jul 09

Fate Therapeutics - FT839 Trial to Initially Target Rheumatoid Arthritis, Vasculitis, Myositis, Lupus, Systemic Sclerosis

THOMSON REUTERS
·
Jul 09

Fate Therapeutics - FT819 Also Being Evaluated in Sle; Phase 2 Trial Planned in Lupus Nephritis

THOMSON REUTERS
·
Jul 06

Fate Therapeutics Reports Preliminary FT819 CAR-T Data Showing Skin Score Improvement in Systemic Sclerosis Patients

Reuters
·
Jul 06

Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences

GlobeNewswire
·
Jul 02